In this Editorial from Bioanalysis, the authors consider the future for hybrid assays following the US FDA recently issued guidance for hybrid assays. Find out more and access the full article, exclusively for Bioanalysis Zone members.
Find out more about the evolution of fit-for-purpose biomarker validations from an LBA perspective in this free article from Bioanalysis.
Parallelism experiments to evaluate matrix effects, selectivity and sensitivity in ligand-binding assay method development: pros and cons
This review compares and discusses all available approaches that can be used to assess key assay parameters for pharmacokinetic and biomarker ligand-binding assays. Find out more in this article from Bioanalysis.
3-(4-Hydroxyphenyl)propionic acid: the forgotten detection substrate for ligand-binding assay-based bioanalysis
In this review article the authors outline the increase in sensitivity and dynamic range when using fluorogenic 3-(4-hydroxyphenyl)propionic acid in preference of other conventional colorimetric ELISA, LBA technologies and LC-MS assays.
Validation of a ligand-binding assay for active protein drug quantification following the ‘free analyte QC concept’
In this research article the authors describe the validation of a ligand-binding assay for active protein drug quantification and address practical challenges as well as regulatory implications.
2016 White Paper on recent issues in bioanalysis: focus on biomarker assay validation (BAV): (Part 3 – LBA, biomarkers and immunogenicity)
In part 3 of this White Paper from this years 10th Workshop on Recent Issues in Bioanalysis (10th WRIB) which took place in Orlando, the authors discuss recommendations for large molecule bioanalysis using LBA, biomarkers and immunogenicity.
2016 White Paper on recent issues in bioanalysis: focus on biomarker assay validation (BAV): (Part 2 – Hybrid LBA/LCMS and input from regulatory agencies)
In part 2 of this White Paper from the 10th Workshop on Recent Issues in Bioanalysis, the authors discuss Hybrid LBA/LCMS and regulatory inputs from major global health authorities.
Considerations for Ligand Binding Assay Platforms: how to choose the right platform to meet your drug development needs
Bioanalytical assays are essential in drug development. In recent years, many new technologies have emerged which offer scientists throughput, sensitivity, multiplexing, and the ability to better understand the data.
Simplify antibody drug conjugate (ADC) bioanalysis challenges with a hybrid LBA/LC-MS assay and pre-developed sample preparation kits.
In this application note, scientists outline best practices and recommendations for LBA reagents.